Dealmaking and Industry Outlook: Geriatric Diseases
Published By: Decision Resources
May 2009
R55-641
PDF E-mail From Publisher $2,250.00
Global Site License Fulfilled by Publisher $4,500.00
Description
Introduction
Rising Medicare costs driven by the aging baby boomers will, within the next few years, propel public national health expenditures in the United States above private national health expenditures for the first time ever.
Increasing expenditures are just one of the healthcare consequences of the rapidly growing elderly demographic in most countries—as people live longer, the costs associated with increased life span grow. Demand for drug treatments that serve this growing cohort is also on the rise. Almost certainly, better drugs and healthcare will be developed to address this important segment of global markets. This report covers therapeutic areas that have the greatest effect on the geriatric population (including cardiology, metabolic, neurology, and respiratory areas) through 25 data-rich figures and tables, as well as insights from Decision Resources analysts.
Questions Answered in This Report
- Most personal health expenditures in the United States are spent on indications that greatly affect the elderly.
What are these therapeutic indications? How much money do U.S. residents spend on these indications?
- The seven major markets differ in their prescription drug coverage. How do these countries cover their elderly?
Do markets other than the U.S. market offer healthcare coverage specifi c to the elderly population?
- Current treatments for diseases afflicting the elderly have advantages and disadvantages. What are the opinions
of Decision Resources analysts regarding these treatments? What are the most promising treatments?
What characteristics of geriatric patients should drug developers consider when targeting this segment?
Scope
- Population demographics: past, current, and projected elderly populations; life expectancy in the
major markets; life expectancy in the United States.
- U.S. healthcare expenditures: total healthcare expenditures, healthcare expenditures as a percentage
of GDP, sources of healthcare expenditure.
- Therapeutic areas affecting the elderly: cardiovascular, metabolic, respiratory, musculoskeletal, central
nervous system, genitourinary, ophthalmology, oncology.
- Deals affecting companies making drugs that serve the elderly population: cardiovascular, diabetes,
respiratory, central nervous system, ophthalmology, osteoporosis, and osteoarthritis.
|
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Trends in Elderly Populations
- Population Growth and Life Expectancy
- The Cost of Living Longer
- National Health Expenditures in the United States: 1993-2018
- Personal Health Expenditures: Where Are We Spending Our Healthcare Money?
- Worldwide Pharmaceutical Market
- Diseases Affecting the Elderly
- Cardiovascular Therapy Area
- Metabolic Therapy Area
- Respiratory Therapy Area
- Musculoskeletal/Pain Therapy Area
- Rheumatoid Arthritis
- Neuropathic Pain
- Osteoarthritis
- Osteoporosis
- Central Nervous System Therapy Area
- Alzheimer’s Disease
- Parkinson’s Disease
- Genitourinary Therapy Area
- Erectile Dysfunction
- Urinary Incontinence
- Ophthalmology Therapy Area
- Oncology Therapy Area
- Healthcare Coverage for the Elderly
- United States
- France
- Germany
- Italy
- Spain
- United Kingdom
- Japan
- Decision Resources Analyst Insights
- Convenience and Compliance
- Determining Patient Genotypes
- Disease Progression and Biomarkers
- Disease-Modifying Therapies
- FDA Guidelines for Developers of Diabetes Drugs
- Lifestyle Drugs and Aging
- Multimorbidity
- Never Too Old
- Nothing Beats Innovation
- Nutrition
- Therapeutic Window
- Outlook
- Tables
- 1. Market-Leading Drugs and Promising Emerging Therapies in Cardiovascular Disease, and 2009
- 2. Market-Leading Drugs and Promising Emerging Therapies in Type 1 Diabetes, 2008 and 2009
- 3. Market-Leading Drugs and Promising Emerging Therapies in Respiratory Disorders, and 2009
- 4. Market-Leading Drugs and Promising Emerging Therapies in Musculoskeletal/Pain Disorders,2008 and 2009
- 5. Market-Leading Drugs and Promising Emerging Therapies in Central Nervous System Disorders,2008 and 2009
- 6. Market-Leading Drugs and Promising Emerging Therapies in Erectile Dysfunction, 2008 and 2009
- 7. Market-Leading Drugs and Promising Emerging Therapies in Age-Related Macular Degeneration,
- 2008 and 2009
- 8. Market-Leading Drugs and Promising Emerging Therapies in Oncology, 2008 and 2009
- 9. Major Pharmaceutical/Biotech Deals Affecting Geriatric Disorders, January 2005-March 2009
- Figures
- 1. Past, Current, and Projected Populations of People Aged 65 Years or Older in the Major Markets for Select Years, 1996-2050
- 2. Life Expectancy at Birth in the United States, Europe, and Japan for Select Years, 2000-2050
- 3. U.S. Life Expectancy at Birth, Age 65, and Age 85 for Select Years, 1900-2005
- 4. U.S. National Health Expenditures for Select Years, 1993-2018
- 5. U.S. National Health Expenditures by Source of Funds for Select Years, 1993-2018
- 6. Contributions of Select Therapeutic Areas and Preventive Care to U.S. Personal Health Expenditures for Select Years, 1996-2005
- 7. Worldwide Pharmaceutical Market, by Therapy Area, 2007
- 8. Percentage of People in the United States Aged 65 Years or Older with Self-Reported Chronic Health Conditions, 2005-2006
- 9. Market Share of Major Players in the Cardiovascular Therapy Area, 2007
- 10. Market Share of Major Players in the Metabolic Therapy Area, 2007
- 11. Market Share of Major Players in the Respiratory Therapy Area, 2007
- 12. Market Size and Major Players in the Musculoskeletal/Pain Therapy Area, 2007
- 13. Market Size and Major Players in the Central Nervous System Therapy Area, 2007
- 14. Market Size and Major Players in the Genitourinary Therapy Area, 2007
- 15. Market Size and Major Players in the Ophthalmology Therapy Area, 2007
- 16. Market Size and Major Players in the Oncology Therapy Area, 2007
|
Order Form * Please reference product number R55-641 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
